» Articles » PMID: 22429108

Zinc Finger Protein Designed to Target 2-long Terminal Repeat Junctions Interferes with Human Immunodeficiency Virus Integration

Overview
Journal Hum Gene Ther
Specialties Genetics
Pharmacology
Date 2012 Mar 21
PMID 22429108
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Integration of the human immunodeficiency virus type 1 (HIV-1) genome into the host chromosome is a vital step in the HIV life cycle. The highly conserved cytosine-adenine (CA) dinucleotide sequence immediately upstream of the cleavage site is crucial for integrase (IN) activity. As this viral enzyme has an important role early in the HIV-1 replication cycle, interference with the IN substrate has become an attractive strategy for therapeutic intervention. We demonstrated that a designed zinc finger protein (ZFP) fused to green fluorescent protein (GFP) targets the 2-long terminal repeat (2-LTR) circle junctions of HIV-1 DNA with nanomolar affinity. We report now that 2LTRZFP-GFP stably transduced into 293T cells interfered with the expression of vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped lentiviral red fluorescent protein (RFP), as shown by the suppression of RFP expression. We also used a third-generation lentiviral vector and pCEP4 expression vector to deliver the 2LTRZFP-GFP transgene into human T-lymphocytic cells, and a stable cell line for long-term expression studies was selected for HIV-1 challenge. HIV-1 integration and replication were inhibited as measured by Alu-gag real-time PCR and p24 antigen assay. In addition, the molecular activity of 2LTRZFP-GFP was evaluated in peripheral blood mononuclear cells. The results were confirmed by Alu-gag real-time PCR for integration interference. We suggest that the expression of 2LTRZFP-GFP limited viral integration on intracellular immunization, and that it has potential for use in HIV gene therapy in the future.

Citing Articles

Validation of Promoters and Codon Optimization on CRISPR/Cas9-Engineered Jurkat Cells Stably Expressing αRep4E3 for Interfering with HIV-1 Replication.

Chupradit K, Sornsuwan K, Saiprayong K, Wattanapanitch M, Tayapiwatana C Int J Mol Sci. 2022; 23(23).

PMID: 36499376 PMC: 9738563. DOI: 10.3390/ijms232315049.


Engineered Zinc Finger Protein Targeting 2LTR Inhibits HIV Integration in Hematopoietic Stem and Progenitor Cell-Derived Macrophages: In Vitro Study.

Chupradit K, Khamaikawin W, Sakkhachornphop S, Puaninta C, Torbett B, Borwornpinyo S Int J Mol Sci. 2022; 23(4).

PMID: 35216446 PMC: 8875109. DOI: 10.3390/ijms23042331.


Stem Cell Therapy and Its Significance in HIV Infection.

Khalid K, Padda J, Wijeratne Fernando R, Mehta K, Almanie A, Hennawi H Cureus. 2021; 13(8):e17507.

PMID: 34595076 PMC: 8468364. DOI: 10.7759/cureus.17507.


2LTRZFP Interacts Specifically to HIV-1 DNA without Off-Target Effects as Determined by Biolayer Interferometry.

Chupradit K, Thongkum W, Juntit O, Sornsuwan K, Tayapiwatana C Biosensors (Basel). 2021; 11(3).

PMID: 33800287 PMC: 8001305. DOI: 10.3390/bios11030076.


Protein Delivery of Cell-Penetrating Zinc-Finger Activators Stimulates Latent HIV-1-Infected Cells.

Perdigao P, Cunha-Santos C, Barbas 3rd C, Santa-Marta M, Goncalves J Mol Ther Methods Clin Dev. 2020; 18:145-158.

PMID: 32637446 PMC: 7317221. DOI: 10.1016/j.omtm.2020.05.016.


References
1.
Agosto L, Yu J, Dai J, Kaletsky R, Monie D, ODoherty U . HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology. 2007; 368(1):60-72. PMC: 2140271. DOI: 10.1016/j.virol.2007.06.001. View

2.
LaFemina R, Callahan P, Cordingley M . Substrate specificity of recombinant human immunodeficiency virus integrase protein. J Virol. 1991; 65(10):5624-30. PMC: 249082. DOI: 10.1128/JVI.65.10.5624-5630.1991. View

3.
Liem S, Ramezani A, Li X, Joshi S . The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance. Hum Gene Ther. 1993; 4(5):625-34. DOI: 10.1089/hum.1993.4.5-625. View

4.
Vercruysse T, Pardon E, Vanstreels E, Steyaert J, Daelemans D . An intrabody based on a llama single-domain antibody targeting the N-terminal alpha-helical multimerization domain of HIV-1 rev prevents viral production. J Biol Chem. 2010; 285(28):21768-80. PMC: 2898381. DOI: 10.1074/jbc.M110.112490. View

5.
Grant P, Zolopa A . Integrase inhibitors: a clinical review of raltegravir and elvitegravir. J HIV Ther. 2008; 13(2):36-9. View